MITEM

MITEM Pharma is a French specialty pharmaceutical company dedicated to the acquisition, revival, and commercialization of "Drugs of Major Therapeutic Interest" (DMTIs). Established in 2016 by industry veterans Claude-Alain Cudennec and Éric Thierry, the company addresses critical public health needs by ensuring the availability of essential medicines that face supply shortages or market withdrawal. MITEM Pharma's strategy involves acquiring established brands from large pharmaceutical companies, such as FLISINT (fumagillin) from Sanofi and DESFERAL (deferoxamine) from Novartis, and leveraging its international distribution network spanning over 60 countries. The company is backed by TechLife Capital and focuses on therapeutic areas including hematology, endocrinology, infectious diseases, and emergency cardiology.